ZYNE

Zynerba Pharmaceuticals, Inc. (ZYNE) | Rumor.io

Zynerba Pharmaceuticals

ZYNE

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ZYNE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 15

Zynerba Pharmaceuticals has a market cap of $17 million and net cash of $45 million, with a slow cash burn and significant clinical trials and FDA approval progress.
The company's stock price has increased from $0.39 to $1.36, with some investors expressing regret over not investing more.
Analysts have downgraded Zynerba Pharmaceuticals to Neutral from Buy, with one potential catalyst being a potential $200M buyout.

Generated by AI

Sentiment

Of the messages about ZYNE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Bullish· Mar 15

$ZYNE has shown significant price increases, including a 25.69% gain in a single day and a 13% gain on 5M volume.
The company's stock has experienced a strong upward trend, with multiple posts highlighting its potential for further growth and profit.
$ZYNE has broken above key price levels, such as $5 and $7, which is considered a bullish indicator by some market participants.

Bearish· Feb 11

$ZYNE has seen a significant price drop, with some investors selling at discounted prices.
The asset's price movement is being driven by short sellers, with many anticipating further declines.
Despite some investors expecting a rebound, $ZYNE's price has already fallen by over 30% in a short period.

Generated by AI

Topics

Of the messages about ZYNE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Earnings· Aug 1

$ZYNE is expected to release earnings before the market opens on Thursday.
Analysts predict a loss of $0.77 per share for the company.
The earnings release is scheduled to take place on Thursday.

Analysts· Aug 15

Zynerba Pharmaceuticals ($ZYNE) was upgraded to "Buy" by Roth Capital, with a price target of $15.
Jefferies downgraded $ZYNE to "Hold" from "Buy", with a new price target of $7, down from $12.
HC Wainwright and CIBC reaffirmed their price targets for $ZYNE at $7 and reiterated a "Market Perform" rating, respectively.

Announcements· Aug 14

Harmony Biosciences is acquiring Zynerba Pharmaceuticals for up to $200M in cash, with Zynerba's shares up 300% pre-market.
Zynerba investors will also receive one non-tradeable contingent value right (CVR) valued at up to $2.5444 per share, or $140M in additional cash payments, subject to certain clinical, regulatory, and sales milestones.
The acquisition is seen as a cheap deal for Harmony Biosciences, with Zynerba having $36M in cash and the CVR potentially worth up to $140M.

Technical Analysis· Apr 3

$ZYNE has broken out of a formation and is likely to continue its uptrend, with a potential target of 13-14.
The stock has formed a textbook 5-minute cup and handle pattern, but volume is not strong enough yet to confirm the breakout.
A potential reversal is possible if $ZYNE's RSI cools down and refuels, but for now, the stock is likely to continue its upward momentum.

Generated by AI

Community

Of the messages about ZYNE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	61.49%
Newcomers	—	—	—	38.51%

Regulars· Aug 14

Zynerba Pharmaceuticals, Inc. ($ZYNE) has been acquired by Harmony Biosciences for $1.10 per share in cash, with the deal valuing the company at up to $200 million.
The acquisition includes a contingent value right (CVR) that could provide investors with an additional $140 million in cash payments, subject to the achievement of certain clinical, regulatory, and sales milestones.
The CVR is valued at up to $2.5444 per share, which could result in additional payments of up to $140 million, contingent on the company's performance in the coming months.

Newcomers· Aug 14

Newcomers are focusing on the potential for a buyout, with some highlighting the significant premium being paid by Harmony Biosciences.
The CVR (contingent value right) associated with Zynerba Pharmaceuticals is being closely watched, with some investors expressing uncertainty about its value.
The stock's price action is being influenced by a trading halt, with some newcomers commenting on the halt and its potential impact on the stock's future performance.

Generated by AI

Also Discussed

Investors talking about ZYNE also mention

#	Name	Attention
1	CARA - Cara Therapeutics, Inc.	——
2	Corbus Pharmaceuticals Holdings, Inc.CRBP	0%0
3	Akerna CorpKERN	0%new
4	Cronos Group Inc.CRON	0%+0
5	Aurora Cannabis Inc.ACB	0%-0.01
6	Bio-Path Holdings Inc.BPTH	0%0
7	IGC Pharma Inc.IGC	0.01%+0
8	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
9	Canopy Growth CorporationCGC	0%-0.01
10	Amplify Alternative Harvest ETFMJ	0%new